ArticlePDF Available

The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin

Authors:

Abstract and Figures

HER-2 is an important oncoprotein overexpressed in about 15-25% of breast cancers. We hypothesized that the ability of curcumin to downregulate HER-2 oncoprotein and inhibit the signal transduction pathway of PI3K/Akt, MAPK, and NF-κB activation may be important in the treatment of HER-2-overexpressed breast cancer. To examine the effect of curcumin on breast cancer cells, MCF-7, MDA-MB-231, MCF-10A, BT-474, and SK-BR-3-hr (a herceptin resistant strain from SK-BR-3) cells were used for in vitro analysis. The in vivo effect of curcumin on HER-2-overexpressed breast cancer was investigated with the HER-2-overexpressed BT-474 xenograft model. Cell growth, cell cycle change, the antimobility effect, signal transduction, and xenograft volume analysis between groups treated with herceptin and/or curcumin were tested. Curcumin decreased the cell growth of various breast cancer cell lines (MCF-7, MDA-MB-231, MCF-10A, BT-474, and SK-BR-3-hr). In Western blot analysis, the phosphorylation of Akt, MAPK, and expression of NF-κB were reduced in BT-474 cells, but not in SK-BR-3-hr cells, after treatment with herceptin. When treated with curcumin, the HER-2 oncoprotein, phosphorylation of Akt, MAPK and expression of NF-κB were decreased in both BT-474 and SK-BR-3-hr cells. In the BT-474 xenograft model, though not as much as herceptin, curcumin did effectively decrease the tumor size. The combination of curcumin with herceptin was not better than herceptin alone; however, the combination of taxol and curcumin had an antitumor effect comparable with taxol and herceptin. The results suggested that curcumin has potential as a treatment for HER-2-overexpressed breast cancer.
Content may be subject to copyright.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 486568, 12 pages
doi:10.1155/2012/486568
Research Article
The Potential Utility of Curcumin in the Treatment of
HER-2-Overexpressed Breast Cancer: An
In Vitro
and
In Vivo
Comparison Study with Herceptin
Hung-Wen Lai,1, 2 Su-Yu Chien,3, 4, 5 Shou-Jen Kuo,1, 4, 5 Ling-Ming Tseng,6, 7 Hui-Yi Lin,8
Chin-Wen Chi,2and Dar-Ren Chen1, 4
1Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua 50006, Taiwan
2Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan
3Department of Pharmacology, Changhua Christian Hospital, Changhua 50006, Taiwan
4School of Medicine, College of Health Care and Management, Chung Shan Medical University, Taichung 40201, Taiwan
5School of Nutrition, College of Health Care and Management, Chung Shan Medical University, Taichung 40201, Taiwan
6Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 11217, Taiwan
7School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan
8Department of Pharmacology, School of Pharmacology, China Medical University, Taichung 40402, Taiwan
Correspondence should be addressed to Dar-Ren Chen, darren chen@cch.org.tw
Received 11 November 2010; Revised 21 March 2011; Accepted 2 May 2011
Academic Editor: Jae Youl Cho
Copyright © 2012 Hung-Wen Lai et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
HER-2 is an important oncoprotein overexpressed in about 15–25% of breast cancers. We hypothesized that the ability of curcumin
to downregulate HER-2 oncoprotein and inhibit the signal transduction pathway of PI3K/Akt, MAPK, and NF-κBactivationmay
be important in the treatment of HER-2-overexpressed breast cancer. To examine the eect of curcumin on breast cancer cells,
MCF-7, MDA-MB-231, MCF-10A, BT-474, and SK-BR-3-hr (a herceptin resistant strain from SK-BR-3) cells were used for in vitro
analysis. The in vivo eect of curcumin on HER-2-overexpressed breast cancer was investigated with the HER-2-overexpressed BT-
474 xenograft model. Cell growth, cell cycle change, the antimobility eect, signal transduction, and xenograft volume analysis
between groups treated with herceptin and/or curcumin were tested. Curcumin decreased the cell growth of various breast cancer
cell lines (MCF-7, MDA-MB-231, MCF-10A, BT-474, and SK-BR-3-hr). In Western blot analysis, the phosphorylation of Akt,
MAPK, and expression of NF-κB were reduced in BT-474 cells, but not in SK-BR-3-hr cells, after treatment with herceptin. When
treated with curcumin, the HER-2 oncoprotein, phosphorylation of Akt, MAPK and expression of NF-κB were decreased in both
BT-474 and SK-BR-3-hr cells. In the BT-474 xenograft model, though not as much as herceptin, curcumin did eectively decrease
the tumor size. The combination of curcumin with herceptin was not better than herceptin alone; however, the combination
of taxol and curcumin had an antitumor eect comparable with taxol and herceptin. The results suggested that curcumin has
potential as a treatment for HER-2-overexpressed breast cancer.
1. Introduction
Around 15–25% of breast cancers are noted to overexpress
the human epithelial growth factor receptor 2 (HER-2) [1
3], patients with HER-2 overexpression were associated with
a poor prognosis, more disease relapse, and distant metas-
tasis [36]. Herceptin (generic name: Trastuzumab), which
eectively inhibits the HER-2-related PI3k/Akt and MAPK
pathways, is the first targeted therapeutic agent developed
and approved for the treatment of patients with HER-2-
overexpressed breast cancer [712]. Despite the success of
herceptin, a significant proportion of HER-2-positive breast
cancer patients responded poorly to the treatment [13,14].
In addition, some patients that initially responded to the
therapy became resistant within one year [14,15]. The
refractory state of these HER-2-positive breast carcinomas
2 Evidence-Based Complementary and Alternative Medicine
illustrates the need to examine the mechanisms underlying
tumor resistance and the necessity to seek novel treatment
strategies.
Curcumin (diferuloylmethane) is a yellow pigment de-
rived from the rhizome of the plant Curcuma longa L.
The powdered rhizome of this plant, called turmeric, is
commonly used in the preparation of curries. Curcumin,
as a polyphenol with a diarylheptanoid structure containing
two α,β-unsaturated ketones, is considered to be the major
active constituent of turmeric [16,17]. In addition to its
wide range of pharmacological activities, the anticancer
properties of curcumin have attracted great interest [1820].
The ability of curcumin to downregulate EGFR [19,21,22]
and HER-2 [23] oncoproteins and aect the PI3K/Akt [24]
and MAPK [25] pathways, with which herceptin interfered,
raised interest in the potential utility of curcumin in the
treatment of HER-2-positive breast cancer.
Taxol (generic name: Paclitaxel) combined with her-
ceptin is one of the current preferred regimens for the
treatment of HER-2-overexpressed breast cancer [11,26].
NF-κB is an important factor related to proliferation and
antiapoptosis [27,28], and the activation of NF-κBplays
an important role in the chemoresistance of taxol [29,30].
Curcumin has the well-known ability to downregulate NF-
κB[31,32]. The combination of curcumin with taxol could
suppress taxol-related NF-κB activation and enhance the
antitumor eect of taxol [31,33]. The evolving concept
of combining a monoclonal antibody (herceptin or per-
tuzumab) for the extracellular domain of HER-2 and small
molecule tyrosine kinase inhibitors (TKI) for EGFR (gefi-
tinib, erlotinib) [3436] or EGFR/HER-2 (lapatinib) [37]has
shown benefit in some preclinical studies and patient trials.
The multifunctions of curcumin in downregulating EGFR
and HER-2 oncoproteins, reducing the phosphorylation of
Akt and MAPK and suppressing NF-κB activation, led to
interest in using curcumin in the treatment of HER-2-
overexpressed breast cancer, along with herceptin and/or
taxol.
The aim of this preclinical study was to explore the
potential application of curcumin in the treatment of HER-
2-overexpressed breast cancer and examine the interaction of
curcumin and herceptin, which has rarely been reported.
2. Materials and Methods
2.1. Cell Culture and Reagents. To examine the eect of
herceptin and curcumin on breast cancer cell lines with
various estrogen receptors (ER) and HER-2 receptors, MCF-
7 [ER(+), HER-2()], SK-BR-3-hr (a herceptin-resistant
strain from SK-BR-3 breast cancer cells) [ER(), HER-
2(+)], BT-474 [ER(+), HER-2(+)], MDA-MB-231 [ER(),
HER-2()], and normal breast epithelial cells, MCF-10A
[ER(), HER-2()], were chosen. The expression of HER-
2 oncoprotein in MCF-7, MCF-10A, MDA-MB-231, BT-
474, and SK-BR-3-hr cells was verified by western blotting
(Figure 1).
The cell lines (MCF-7, BT-474, MDA-MB-231, and
normal breast MCF-10A) used in this study were purchased
MCF-10A
MCF-7
MDA-MB-231
BT-474
SK-BR-3-hr
HER-2 (185 kDa)
β-actin (42 kDa)
HER2-
unexpressed
HER2-
overexpressed
Figure 1: The expression of HER-2 oncoprotein in various human
breast cancer cell lines. Cells were lysed and analyzed by western blot
as described in methods. As revealed in figure, BT-474 and SKBr-3-
hr were HER-2-overexpressed breast cancer cell lines. Whiles MCF-
7, MCF-10A, and MDA-MB-231 cells were HER-2-unexpressed
breast cancer cells.
from American Type Culture Collection (ATCC). SK-BR-
3-hr, a herceptin-resistant strain, was a kind gift from
Dr. L.-M. Tseng. The resistance of herceptin was induced
by repeated culture of herceptin-treated SK-BR-3 cells,
which were herceptin-sensitive and purchased from ATCC.
The MCF-7 cell line was maintained in RPMI medium
with 10% fetal bovine serum, 50 unit/mL penicillin, and
50 unit/mL streptomycin. The MDA-MB-231 cells were
cultured in L15 medium containing 10% fetal bovine serum,
50 unit/mL penicillin, and 50 unit/mL streptomycin. BT-474
cells were maintained in DMEM/F12 medium with 10% fetal
bovine serum, 50 unit/mL penicillin, and 50 unit/mL strep-
tomycin. SK-BR-3-hr cells were maintained in DMEM/F12
medium with 10% fetal bovine serum, 50 unit/mL peni-
cillin, and 50 unit/mL streptomycin. MCF-10A was main-
tained in MEBM medium with 1% penicillin-streptomycin,
50 μg/mL hydrocortisone, 1 μg/mL EGF, 500 μg/mL insulin,
and 10 μg/mL cholera toxin. Cells were maintained at 37C
in a humidified atmosphere in the presence of 5% CO2.
2.2. Compounds. Curcumin (Sigma-Aldrich, Inc., St. Louis,
Mo, USA) was dissolved in DMSO at 50 μg/mL as a stock
solution. Herceptin was purchased from Roche and dissolved
in PBS at 50 μg/mL as stock. Taxol was dissolved in 49.7%
ethanol at 6 mg/mL as stock.
2.3. Growth and Cell Proliferation Analysis. Cell proliferation
was measured using sulforhodamine B (SRB) colorimetric
analysis, which is used for cell density determination, based
on the measurement of cellular protein content [38]. The
method described here has been optimized for the toxicity
screening of compounds to adherent cells in a 96-well
format. After an incubation period, cell monolayers were
fixed with 10% (wt/vol) trichloroacetic acid and stained with
SRB for 30 min after which the excess dye was removed
by washing repeatedly with 1% (vol/vol) acetic acid. The
protein-bound dye was dissolved in 10mM Tris base solution
Evidence-Based Complementary and Alternative Medicine 3
for OD determination at 510 nm using a microplate reader.
The results were linear over a 20-fold range of cell numbers.
The trypan blue exclusion test was also used to confirm
the cell proliferation result in herceptin- and curcumin-
treated BT-474 and SK-BR-3-hr cells. Cells were stained with
4% trypan blue (Sigma), and viable cells counted with a
hemocytometer under a light microscope.
2.4. Determination of Combinatorial Eects. The ability of
herceptin and curcumin to act in a synergistic, additive, or
antagonistic matter with regard to growth inhibition was
determined by a combination index (CI) as proposed by
Chou and Talalay [39,40]. The Calcusyn software (Biosoft,
Great Shelford, Cambridge, UK) was used to determine the
CI for each concentration of drug mixture used. A CI value
<1 represented a case where synergism of herceptin and
curcumin was present. CI values of 1 and >1represented
additive and antagonistic eects, respectively.
2.5. Cell Cycle Analysis. Breast cancer cells were plated at a
density of 5 ×105/dish in 60 ×15-mm culture dishes and
allowed to adhere overnight. Cells were then incubated with
media containing herceptin and/or curcumin at dierent
concentrations as indicated. Following 72 hours (h) of
incubation, the cells were washed with PBS, trypsinized, and
collected by centrifugation at 1,500 rpm for 10 minutes. After
centrifugation, the supernatant was removed, and the cell
pelletswerefixedwith75%alcoholat20C.After1hof
incubation, the cell pellets were collected by centrifugation
at 1,500 rpm for 10 minutes. The pellets were incubated with
propidium iodide (PI) solution (10 μg/mL) for 30 minutes.
The cell cycle phase was determined by Cytomics FC500 flow
cytometry (Beckman Coulter).
2.6. Mobility Test. Cell migration is necessary in many
physiological processes, such as wound healing, and is a
characteristic of cancer cell metastasis [41]. The inhibitory
eect of herceptin and/or curcumin on dierent breast
cancer cell lines was tested by wound healing assay. Upon
inflicting a scratch wound, these cells were treated with
various concentrations of curcumin and/or herceptin for 4 h
and returned to standard media in an attempt to minimize
any cytotoxic eects that could potentially confound our
observations. Following 20 h of further incubation, the areas
of the wounds were measured using Image J software
(http://rsb.info.nih.gov/ij/).
2.7. Western Blot Analysis. Breast cancer cells were allowed
to incubate with curcumin and/or herceptin at various
concentrations and time points as indicated and harvested
after treatment. Whole cell lysate was prepared by resus-
pending the cells in RIPA buer supplemented with protease
inhibitors cocktail (PIERCE) and incubating the cells on ice
for 30 minutes. Cell lysates were centrifuged at 13,000 x g
for 10 minutes and the supernatant collected. The protein
concentration was measured using the Bradford assay (Bio-
Rad Laboratories, Hercules, Calif, USA).
An aliquot of protein lysate (10 μg) from each sample
was mixed with 2X Laemmli sample buer (Bio-Rad,
Hercules, Calif, USA), and the protein lysate was separated
in 10% SDS-polyacrylamide gels for 1 h. After transferring
the sample to a nitrocellulose membrane, the membrane
was blocked with 5% milk in 1X TBST buer (10 mM
Tris, 150 mM NaCl, 0.5% Tween-20, pH 7.4) for 1 h at
room temperature and immunoblotted using the following
antibodies: HER-2, phosphorylated Akt (p-Akt), total Akt,
phosphorylated MAPK (p-MAPK), total MAPK, and NF-κB
(Cell Signaling Technology). The proteins were probed with
anti-HER-2 (Cell Signaling Technology), anti-p-Akt, anti-
total Akt, anti-p-ERK1/2, anti-ERK 1/2, anti-NF-κB, and
anti-β-actin (Sigma) at 4C overnight, followed by incuba-
tion with horseradish peroxidase-conjugated secondary anti-
bodies (Sigma). Protein visualization was performed using
the enhanced chemiluminescence kit (PIERCE) according to
the manufacturer protocol. Equal loading of total protein was
normalized with the β-actin signal.
2.8. In Vivo Model: Xenograft of HER-2-Overexpressed Breast
Cancer in Nude Mice. HER-2-overexpressed BT-474 cells
(1 ×107cells per mice) were injected into 4- to 6-week-
old female, athymic nude mice subcutaneously (s.c.) in the
right flank region to form xenografts. Prior to tumor cell
inoculation, all mice were primed with 17β-estradiol pellets
introduced subcutaneously in a biodegradable carrier binder
7 days before inoculation of the tumor (1.7 mg of estradiol
per pellet, Innovative Research of America, Inc.) to promote
tumor growth. Then, 1 ×107BT-474 cells, suspended in
(200 μL) growth-factor-reduced matrigel (BD Bioscience,
Bedford, MA), were injected s.c. into the right flank region.
Aperiodof14to21dayselapsedtoallowformation
of tumor nodules. Tumor nodules were monitored twice
weekly by a single observer using serial micrometer (mm)
measurements, with tumor volume calculated as the product
of length ×width2/2. Six animals were randomly assigned
to each treatment group. Statistical tests were performed to
assure uniformity in starting volumes between treatment and
control groups at the beginning of each experiment.
Treatment groups included the control, herceptin alone,
curcumin alone, and the combination of herceptin and
curcumin. To evaluate the eect of curcumin and/or her-
ceptin with chemotherapeutic agents, taxol alone, taxol and
herceptin, taxol and curcumin, and taxol + herceptin +
curcumin regimens were tested. Treatment with dierent
protocols was initiated 21–28 days postxenograft inoculation
status, at which time the xenograft volume was measured
at around 50–100 mm3.Dierences in xenograft volume on
the 28th posttreatment day between groups were analyzed by
single-factor analysis of variance (ANOVA). The treatment
protocol is summarized.
(a) Control group: sterile 0.1% DMSO intra-peritoneally
(i.p.) injection once per week for 4 consecutive weeks.
(b) Herceptin-only group: loading dose of 4mg/kg her-
ceptin in sterile PBS, administered by i.p. injection,
then a dose of 2 mg/kg maintained at once per week,
for 4 consecutive weeks.
4 Evidence-Based Complementary and Alternative Medicine
(c) Curcumin only: curcumin dissolved in 0.1% DMSO
injected i.p. at a dose of 45 mg/kg twice per week for
4 consecutive weeks.
(d) Combined curcumin and herceptin: curcumin dis-
solved in 0.1% DMSO injected i.p. at a dose of
45 mg/kg twice per week, combined with a loading
dose of 4 mg/kg herceptin in sterile PBS, admin-
istered by i.p. injection, then a dose of herceptin
2 mg/kg maintained at once per week, for 4 consec-
utive weeks.
(e) Taxol-alone group: taxol 10 mg/kg i.p. once per week
for 4 consecutive weeks.
(f) Taxol + herceptin: taxol 10mg/kg i.p. once per week,
combined with a loading dose of 4 mg/kg herceptin in
sterile PBS, administered by i.p. injection, then a dose
of herceptin 2 mg/kg maintained at once per week,
for 4 consecutive weeks.
(g) Taxol and curcumin: taxol 10 mg/kg i.p. once per
week, curcumin dissolved in DMSO injected i.p. at
a dose of 45 mg/kg twice per week for 4 consecutive
weeks.
(h) Taxol, curcumin, and herceptin: taxol 10 mg/kg i.p.
once per week, curcumin dissolved in 0.1% DMSO
injected i.p. at a dose of 45 mg/kg twice per week,
combined with a loading dose of 4 mg/kg herceptin in
sterile PBS, administered by i.p. injection, then a dose
of herceptin maintained at 2 mg/kg once per week,
for 4 consecutive weeks.
After completing 4 weeks of treatment, the mice were
sacrificed before recording body weight and tumor volume.
The tumor was harvested and processed for various ana-
lyticalpurposes.Theanimaluseprotocolwerereviewed
and approved by the Institutional Animal Care and Use
Committee of Changhua Christian Hospital, Changhua,
Taiw a n .
2.9. Statistical Analysis. Analyses were performed using the
Statistical Analysis System (SAS 9.1). Data are presented
as mean ±standard deviation, except where indicated.
Comparisons between groups were analyzed using the chi-
square test, Student’s two-tailed t-test, or one-way ANOVA
with Bonferroni’s correction, as appropriate. A value of P<
0.05 is considered statistically significant.
3. Results
3.1. Eects of Herceptin or Curcumin on Cell Proliferation.
To examine the biological eect of herceptin and curcumin,
breast cancer cell lines were treated with dierent con-
centrations of herceptin (0.1–10 μg/mL) or curcumin (1–
25 μg/mL) for 72 h. Cell proliferation change was assayed
with an SRB assay. As shown in Figure 2(a), in HER-2-
overexpressed BT-474 breast cancer cells, cell proliferation
was inhibited by herceptin in a dose-dependent manner.
Cell proliferation decreased to 60% after treatment with
1μg/mL of herceptin and reached a plateau when with
0
20
40
60
80
100
120
012345678910
Cell growth (%)
Herceptin (μg/mL)
(a)
0
20
40
60
80
100
120
Cell growth (%)
0 5 10 15 20 25
Curcumin (μg/mL)
MCF-7 MDA-MB-231
BT-474 SK-BR-3-hr
MCF-10A
(b)
Figure 2: The eect of herceptin and curcumin on growth of
dierent breast cancer cell lines. Cells were incubated with dierent
levels of herceptin (a) or curcumin (b) for 72 h, respectively, and cell
growth was measured using SRB assay.
a concentration >1μg/mL. In SK-BR-3-hr breast cancer
cells, an HER-2-overexpressed and herceptin-resistant breast
cancer cell line, cell growth was not inhibited by herceptin,
even at a 10 μg/mL high concentration. The growth of MCF-
7 and MCF-10A, which were non-HER-2-overexpressed
cells, was not aected by herceptin treatment. The growth
of MDA-MB-231 cells decreased to 64% of the control after
10 μg/mL of herceptin treatment (Figure 2(a)).
In examining the eect of curcumin treatment on these
cell lines, we found that the cell proliferations of these five cell
lines (MCF-7, BT-474, SK-BR-3-hr, MCF-10A, and MDA-
MB-231) were all decreased after treatment with curcumin,
with dierent sensitivities (Figure 2(b)). The SK-BR-3-hr,
MCF-10A, and MDA-MB-231 cells were more sensitive to
curcumin than BT-474 and MCF-7 cells. After treatment
Evidence-Based Complementary and Alternative Medicine 5
0
20
40
60
80
100
012345678910
Cell growth (%)
Herceptin (μg/mL)
BT-474
No curcumin 5μg/mL curcumin
15 μg/mL curcumin
0
20
40
60
80
100
012345678910
Cell growth (%)
Herceptin (μg/mL)
10 μg/mL curcumin
No curcumin 5μg/mL curcumin
15 μg/mL curcumin
10 μg/mL curcumin
SK-BR-3-hr
(a)
BT-474
No curcumin 5μg/mL curcumin
10 μg/mL curcumin
0
5
10
15
20
25
30
35
40
45
50
55
0 0.1 1 2 5 10
Cell number (1 ×104cells)
Herceptin (μg/mL)
SK-BR-3-hr
0
5
10
15
20
25
30
35
40
45
50
55
00.11 2 5 10
Cell number (1 ×104cells)
Herceptin (μg/mL)
15 μg/mL curcumin
No curcumin 5μg/mL curcumin
10 μg/mL curcumin 15 μg/mL curcumin
(b)
Figure 3: Cell growth of HER-2-overexpressed breast cancer cells with combined treatment of herceptin and curcumin. (a) The combined
eects of herceptin and curcumin on the growth of BT-474 and SK-BR-3-hr cells. Cell growth was analyzed by SRB assay after drug treatment
for 72 h. (b) The combinational eects of herceptin and curcumin on BT-474 and SK-BR-3-hr cells were analyzed by trypan blue exclusion
assay after drug treatment for 72 h.
with 10 μg/mL of curcumin, the cell proliferation of HER-
2-overexpressed BT-474 cells and herceptin-resistant SK-BR-
3-hr cells decreased to 65% and 20%, respectively.
3.2. Combination Treatment of Cells with Herceptin and
Curcumin. Figure 3(a) shows the proliferation of dierent
cell lines after treatment with a combination of herceptin
and curcumin. In the HER-2-overexpressed BT-474 cells,
we found that the antiproliferative eect of herceptin was
not aected by the addition of curcumin. Curcumin could
further decrease the proliferation of BT-474 cells when
combined with herceptin. No apparent synergistic eect was
presented when herceptin was combined with curcumin in
the SK-BR-3-hr cells. The antiproliferative eect was mainly
from curcumin, and the combination of herceptin with
curcumin did not reveal a more antiproliferative eect than
curcumin alone.
Trypan blue exclusion assay confirmed that both her-
ceptin and curcumin inhibited the BT-474 cells dose-
dependently. The combination of herceptin and curcumin
further eectively decreased the cell viability of BT-474
cells (Figure 3(b)). The SK-BR-3-hr cells that we used here
were resistant to herceptin but sensitive to curcumin. The
combination of herceptin and curcumin eectively decreased
6 Evidence-Based Complementary and Alternative Medicine
Tab le 1: The combination index of herceptin and curcumin treatment of the growth of BT-474 cells.
Herceptin (μg/mL) Curcumin (μg/mL) Fa CI Eect
0.1 5 0.34 0.669 Synergistic
0.1 10 0.45 0.836 Synergistic
0.1 15 0.54 0.900 Synergistic
1 5 0.52 0.393 Synergistic
1 10 0.52 0.713 Synergistic
1 15 0.54 0.953 Synergistic
2 5 0.52 0.467 Synergistic
2 10 0.53 0.750 Synergistic
2 15 0.54 1.013 Additive
5 5 0.5 0.794 Synergistic
5 10 0.52 1.007 Additive
5 15 0.56 1.075 Additive
10 5 0.49 1.354 Antagonistic
10 10 0.54 1.195 Antagonistic
10 15 0.57 1.241 Antagonistic
AvalueofCI<1 represents a case where synergism of herceptin and curcumin was present. CI values of 1 and >1 represent additive and antagonistic eects,
respectively. Fa, fraction aected; CI, combination index.
the cell viability of SK-BR-3-hr cells. However, no apparent
synergistic or antagonistic eect was present in SK-BR-3-hr
cells when a combination of herceptin and curcumin was
used.
The combination eectofherceptinandcurcuminonthe
growth of BT-474 breast cancer cells was further analyzed
with Calcusyn software for calculation of the CI. The
combination of herceptin with curcumin exerted a biphasic
interaction in BT-474 cells. The CI was less than 1 and
showed a synergistic eect in the following conditions: a
lowdoseofherceptin(0.11μg/mL) with curcumin (5–
15 μg/mL), 2 μg/mL herceptin with curcumin (5–10 μg/mL),
or 5 μg/mL herceptin with curcumin 5 μg/mL. The CI was
larger than 1 and showed an antagonistic eect when using
a high dose of herceptin (>10 μg/mL) with curcumin (5–
15 μg/mL). The CI and interaction between herceptin and
curcumin in BT-474 cells are summarized in Ta b l e 1 .
3.3. Eect of Herceptin and/or Curcumin on HER-2-Related
Akt and MAPK Pathways in BT-474 and SK-BR-3-hr Cells.
In the HER-2-overexpressed BT-474 and SK-BR-3-hr cells,
phosphorylation of Akt and MAPK was observed (Figure 4).
Herceptin dose-dependently inhibited the phosphorylation
of Akt and MAPK in BT-474 breast cancer cells (left
panel, Figure 4(a)). HER-2 oncoprotein was not depleted by
herceptin treatment, even at high concentrations (10 μg/mL).
The addition of herceptin on SK-BR-3-hr cells did not
decrease the expression of HER-2 oncoprotein nor decrease
the phosphorylation of Akt and MAPK, even at a 10 μg/mL
concentration (right panel, Figure 4(a)). This was compati-
ble with the fact that this SK-BR-3-hr cell line was a strain
resistant to herceptin. When treated with curcumin, the
phosphorylation of Akt and MAPK was decreased, combined
with the downregulation of HER-2 oncoprotein, in a dose-
dependent manner in both the BT-474 and SK-BR-3-hr cells
(Figure 4(b)).
The level of NF-κB in BT-474 cells was decreased along
with the decreased phosphorylation of Akt and MAPK after
treatment with herceptin. The level of NF-κB was increased,
even in high concentrations of herceptin-treated SK-BR-3-
hr cells. When treated with curcumin, the level of NF-κB
was decreased in a dose-dependent manner in both BT-474
and SK-BR-3-hr cells. The combination of herceptin and
curcumin treatment resulted in a decreased level of HER-2
oncoprotein, p-Akt, p-MAPK, and NF-κB in both BT-474
and SK-BR-3-hr cells (Figure 4(c)).
3.4. Eect of Curcumin and/or Herceptin on BT-474 Breast
Cancer Cell Cycle. To further characterize the eects of
curcumin and/or herceptin on breast cancer cell growth,
analyses of cell cycle phase distribution were conducted. The
cell cycle of BT-474 cells without drug treatment showed a
G0/G1 phase of 74%, S phase of 19%, and G2/M phase of
7%. When treated with herceptin, the G0/G1 phase increased
from 74% to 79%, the S phase decreased from 19% to 11%,
and the G2/M phase increased from 7% to 10%. When
BT-474 cells were treated with curcumin, the G0/G1 phase
remained at 74%, the S phase decreased from 19% to 9%,
and G2/M increased from 7% to 20%. The combination
of 1 μg/mL of herceptin with 10 μg/mL curcumin showed
a decrease in the S phase (from 19% to 12%) without an
apparent change in the G0/G1 (from 74% to 78%) and G2/M
phases (7% to 10%). The results indicated that no significant
change in cell cycle progression was observed in BT-474 cells
after treatment with herceptin and/or curcumin.
In SK-BR-3-hr cells, the cell cycle was not changed
after treatment with herceptin, which is compatible with
Evidence-Based Complementary and Alternative Medicine 7
0 0.1 1 2 5 10
1 0.9 0.9 0.9 0.9 0.9
1 0.5 0.5 0.9 0.9 0.3
1 1 1 0.9 0.5 0.1
1 1 0.5 0.5 0.25 0.25
Herceptin (μg/mL)
HER-2
p-Akt
Total Akt
p-MAPK
Total MAPK
NF-κB
β-actin
BT-474 SK-BR-3-hr
0 0.1 1 2 5 10
1 0.9 0.9 0.9 0.9 0.9
1 0.5 0.5 0.9 0.9 1.3
1 1 1 1.5 1.5 1.5
1 1 1 1.5 2 2.5
(a)
0 1 2.5 5 10 25 0 1 2.5 5 10 25
11110.10
1 1 1 0.5 0.3 0.3
111110.5
1 1.5 1 1 0.5 0.1
11110.50.1
1 1 1 0.5 0.3 0.1
1 1 1 0.5 0.5 0.5
1 1.5 1 1 1 0.1
Curcumin(μg/mL)
HER-2
p-Akt
Total Akt
p-MAPK
Total MAPK
NF-κB
β-actin
BT-474 SK-BR-3-hr
(b)
10 μg/mL herceptin
10 μg/mL curcumin
1 0.8 0.8 0.5
1 0.1 0.2 0.1
1 0.5 0.9 0.5
1 0.01 0.1 0.01
1 0.9 0.9 0.5
1 0.5 0.9 0.5
1 1.5 2 1
1 0.9 0.5 0.5
++++
++++
HER-2
p-Akt
Total Akt
p-MAPK
Total MAPK
NF-κB
β-actin
BT-474 SK-BR-3-hr
(c)
Figure 4: The level of HER-2, phosphorylated Akt, MAPK, and NF-κB after treatment with herceptin and/or curcumin in HER-2-
overexpressed breast cancer cells. The dosage eects of herceptin (a), curcumin (b), and the combination of herceptin and curcumin (c)
on the BT-474 and SK-BR-3-hr cells, respectively. The number at the bottom of each lane indicates the relative fold change of control.
the resistance of this cell line. When treated with curcumin
for 48 h, the cell cycle of SK-BR-3-hr showed a decrease in
the G1 phase (65% to 37%) and an increase in the S phase
(28% to 37%) and G2/M phase (6% to 25%). Compared
with the control, the combination of 1 μg/mL herceptin and
10 μg/mL curcumin showed a decrease in the G1 (65% to
53%), no apparent change in the S phase (28% to 27%), and
an increase in the G2/M phase (6% to 19%).
3.5. Eect of Curcumin and/or Herceptin on the Mobility of
Dierent Breast Cancer Cells. The inhibitory eect of her-
ceptin and/or curcumin on dierent breast cancer cell lines
was tested by wound-healing assay. Curcumin showed an
apparent antimobility eect as illustrated in the MCF-7,
MDA-MB-231, and SK-BR-3-hr cells (Figure 5). No eect
of herceptin and/or curcumin on the mobility of BT-474
cells was observed due to the lack of migration of these
cells. In the SK-BR-3-hr cells, cell migration persisted despite
treatment with herceptin, which is consistent with herceptin
resistance. When treated with curcumin, cell migration was
greatly inhibited as compared with the control, revealing that
curcumin had an apparent antimobility eect on SK-BR-3-
hr cells. The combination of herceptin and curcumin did
not have a better antimobility eect than curcumin alone.
In the wound healing assay, curcumin showed an apparent
antimobility eect in MCF-7, SK-BR-3-hr, and MBA-MB-
231 breast cancer cells.
3.6. Curcumin and/or Herceptin Inhibited Tumor Growth
in the Xenograft Animal Model. Compared with the con-
trol group, the mice treated with curcumin, herceptin,
or combined herceptin and curcumin all had a smaller
mean xenograft tumor volume after 4 weeks of treatment
(control group 273.6 ±190.1 mm3, curcumin group 63.6 ±
25.7 mm3, herceptin group 36.3 ±7.8 mm3, and combined
herceptin and curcumin group 34.1 ±25.0 mm3,P=0.001)
8 Evidence-Based Complementary and Alternative Medicine
0h
24 h
0h
24 h
0h
24 h
MCF-7
MDA-MB-231SK-BR-3-hr
100 102030405060708090100
Mobility (μm)
Control
10 μg/mL herceptin
10 μg/mL curcumin
10 μg/mL herceptin +10 μg/mL curcumin
∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗∗
∗∗
∗∗∗
∗∗∗
10 μg/mL herceptin
10 μg/mL curcumin
20
9
9
19
8
8
33
72
39
38
97
38.5
++
−− ++
Figure 5: Changes in mobility of MCF-7, MDA-MB-231, and SK-BR-3-hr cells after treatment with herceptin and/or curcumin. The
antimobility eect of herceptin and/or curcumin on breast cancer cells were tested by a wound-healing assay. The anti-mobility eect was
illustrated in the MCF-7, MDA-MB-231 and SK-BR-3-hr cells, respectively. P<0.05; ∗∗P<0.01; ∗∗∗P<0.001.
(Figure 6(a)). The curcumin alone group had a larger mean
xenograft tumor size than the herceptin-alone group (63.6 ±
25.7 mm3versus 36.3 ±7.8 mm3,P=0.003). The combined
herceptin and curcumin group showed a smaller mean tu-
mor volume than the curcumin-alone group (34.1 ±25.0
versus 63.6 ±25.7 mm3,P=0.079) or herceptin-alone
group (34.1 ±25.0 versus 36.3 ±7.8 mm3,P=0.324),
although without statistical significance.
The eect of combining curcumin and/or herceptin
with taxol was tested by comparing the eects of taxol,
taxol + herceptin, taxol + curcumin, and taxol + herceptin
+ curcumin regimens in the BT-474 xenograft model. In
another set of experiments, 24 mice inoculated with 1 ×
107BT-474 cells were randomized into 4 groups and treated
with taxol, taxol + herceptin, taxol + curcumin, or combined
taxol + herceptin + curcumin. After 4 weeks of treatment, the
mean xenograft tumor volumes were taxol 58.3 ±11.2 mm3,
taxol+herceptin35.0±13.4 mm3, taxol + curcumin 44.5
±6.2 mm3, and combined taxol + herceptin + curcumin
group 31.3 ±27.7 mm3.Theantitumoreect of taxol +
herceptin was apparent, and combined taxol and curcumin
had a comparable antitumor eect (44.5 ±6.2 versus
Evidence-Based Complementary and Alternative Medicine 9
0
50
100
150
200
250
300
01234
Time after treatment (week)
Tumor volume (mm)
Control Herceptin + curcumin
Herceptin Curcumin
(a)
01234
Time after treatment (week)
0
20
40
60
80
100
Tumor volume (mm)
Taxo l Taxol+herceptin
Taxol + curcumin Taxol + herceptin + curcumin
(b)
0
3
6
9
12
15
18
21
24
Weight (g)
01234
Time after treatment (week)
Control Herceptin + curcumin
Herceptin Curcumin
(c)
Figure 6: In vivo eects of curcumin on the herceptin and/or taxol-treated HER-2-overexpressed breast cancer xenografts. The HER-2-
overexpressed BT-474 cells were injected in 4–6-week-old, female, athymic, nude mice subcutaneously at 1 ×107cells/tumor in the right
flank region to form xenografts. Six mice per group were treated with dierent protocols with tumor volume monitored biweekly for
consecutive 4 weeks. (a) The mean xenograft tumor volume change of control (0.1% DMSO), herceptin, curcumin, and combined curcumin
and herceptin. (b) The mean xenograft tumor volume of taxol, taxol + herceptin, taxol + curcumin, and combined taxol + herceptin +
curcumin. (c) The body weight change of these mice treated with herceptin and/or curcumin. DMSO, dimethyl sulfoxide.
35.0 ±13.4 mm3,P=0.884). The combination of taxol,
herceptin, and curcumin resulted in the smallest tumor
volume, but this was not statistically dierent from that of
the taxol and herceptin regimen (31.3 ±27.7 versus 35.0
±13.4 mm3,P=0.079) (Figure 6(b)). The body weight of
these mice treated with herceptin and/or curcumin was quite
stable during the 4-week period (Figure 6(c)).
4. Discussion
This study was designed to test the ecacy of curcumin
in HER-2-overexpressed breast cancer, with a direct com-
parison with herceptin in the in vitro cell line and in vivo
xenograft animal model. Our preclinical result revealed that
curcumin reduced the cell viability of dierent breast cancer
cell lines, including MCF-7 (ER-positive, HER-2-negative),
MDA-MB-231 (ER-negative, HER-2-negative), HER-2-over-
expressed BT-474 (ER-positive, HER-2-positive), and her-
ceptin-resistant SK-BR-3-hr (ER-negative, HER-2-positive)
cells. The level of HER-2 oncoprotein, p-Akt, p-MAPK,
and NF-κB were decreased in a dose- and time-dependant
manner in BT-474 and SK-BR-3-hr cells when treated with
curcumin. The cell cycle perturbation by curcumin was
mainly found in the increase in the G2/M phase. The
apparent antimobility eect of curcumin was also revealed
in the MCF-7, MDA-MB-231, and SK-BR-3-hr cells. The
combinational eect of herceptin with curcumin was a
biphasic interaction on the growth of BT-474 cells. When
a low dose of herceptin was used with curcumin, there was
a synergistic eect, but an antagonistic eect was observed
when a high dose of herceptin was used. In the BT-474
xenograft model, curcumin treatment eectively decreased
10 Evidence-Based Complementary and Alternative Medicine
the tumor size, and the combination of taxol with curcumin
had an antitumor eect comparable with that of taxol and
herceptin treatment.
The action of herceptin in inhibiting ErbB2 (HER-
2) signaling involves the reduced phosphorylation of Akt
but not endocytic downregulation of ErbB2 [42]. HER-2
oncoprotein was not depleted by herceptin, even at a high
concentration (Figure 4). The exact mechanism of herceptin
resistance is not clear, and possible mechanisms include
obstacles to herceptin-binding to HER-2, upregulation of
HER-2 downstream signaling pathways, signaling through
alternative pathways, or failure to trigger immune-mediated
mechanisms to destroy tumor cells [14]. In the herceptin-
resistant SK-BR-3-hr cells, the persistent activation of
PI3K/Akt and MAPK pathways, despite treatment with
herceptin, may have been acquired through repeated cultures
of herceptin-treated SK-BR-3 cells.
NF-κB activation played an important role in chemother-
apy resistance [29,30], and targeting NF-κB showed im-
proved benefits in some preclinical HER-2-overexpressed
cancer cells [28,43]. In HER-2-overexpressed breast cancer,
ErbB2 activates NF-κB via signaling that includes PI3K,
PDK1, Akt, protein kinase 2 (CK2), and CKBBP1 [44]. In
herceptin-sensitive HER-2-overexpressed BT-474 cell lines,
herceptin treatment eectively decreased the phosphoryla-
tion of Akt, MAPK and the expression of NF-κB(Figure 4).
Whether the resistance to herceptin was also related to NF-
κB activation is not clear. In the herceptin-resistant SK-BR-
3-hr cells, the expression level of NF-κB increased in parallel
with the incremental dose of herceptin. When treated with
curcumin, the expression of NF-κBwasdecreased,accom-
panied with increased cell death. The ability of curcumin to
inhibit herceptin-resistant SK-BR-3 cells may be related to
the downregulation of HER-2 oncoprotein, and suppression
of related Akt, MAPK, and NF-κB signaling pathways. The
ability of curcumin to downregulate EGFR and HER-2
oncoproteins and inhibit the phosphorylation of Akt and
MAPK and NF-κB activation suggests that curcumin has
potential in the treatment of HER-2-overexpressed and/or
herceptin-resistant breast cancer.
The interaction of curcumin and herceptin in HER-2-
overexpressed cancer has rarely been reported. Whether the
combination of herceptin with curcumin had any therapeu-
tic advantage over herceptin alone is unknown. In the in
vitro BT-474 cell line study, the combination of herceptin and
curcumin showed an advantage over either treatments alone
(Figure 3). The combination of herceptin and curcumin
exerted a biphasic interaction on the growth of BT-474 cells.
A synergistic eect was present when a low dose of herceptin
(0.1–1 μg/mL) was combined with curcumin, while a high
dose (>10 μg/mL) of herceptin would exert an antagonistic
eect when combined with curcumin (Tabl e 1 ). In the SK-
BR-3-hr cells, the combination of herceptin with curcumin
exerted neither a synergistic nor antagonistic eect. This
biphasic interaction observed in vitro warrants caution when
herceptin is to be used with curcumin or other medications.
In the xenograft animal study, curcumin treatment eec-
tively reduced the tumor volume by 76.7%, compared with
the control; however, it was not as eective as of herceptin,
which achieved an 86.7% tumor reduction (Figure 6(a)). The
combination of herceptin and curcumin showed a greater
antitumor eect than curcumin alone (87.5% versus 76.7%
in tumor regression) but a similar eecttothatofherceptin
(87.5% versus 86.7%). The anticipated synergistic eect of
combining herceptin with curcumin was not observed in
our in vivo xenograft animal model. Although curcumin
might not interfere with herceptin in the normal physiologic
concentration, from our in vivo study, combined herceptin
and curcumin was not better than herceptin alone. More
solid evidence might be needed to support the rationale of
combing herceptin with curcumin in the treatment of HER-
2-overexpressed breast cancer.
It has been reported that curcumin could suppress taxol-
induced NF-κB, and curcumin combined with taxol showed
greater antitumor eects than taxol alone [31,33]. In our
in vivo xenograft study, the combination of curcumin and
taxol had therapeutic eects comparable with taxol and
herceptin, one of the current preferred regimens for HER-2-
overexpressed breast cancer (Figure 6(b)). The combination
of taxol + herceptin + curcumin was associated with the
smallest mean tumor volume although this was not statis-
tically dierent from that of the taxol and herceptin regimen.
Curcumin was rated safe and well-tolerated [45]; how-
ever, the application of curcumin might be limited by its
low bioavailability [16,17,45,46]. To reduce the impact
of the low bioavailability of oral intake, we used an intra-
peritoneal injection to treat xenograft nude mice. In our
study, the body weight of herceptin and curcumin-treated
mice did not vary greatly during the entire treatment
period (Figure 6(c)), demonstrating the relative safety and
tolerability of curcumin as previously reported in animal
and human studies [16,47,48]. The main limitation of
our in vivo study was that we had only one fixed dose
protocol for herceptin and/or curcumin treatment, and the
serum concentration of the drugs was unknown. The dose
of herceptin used here was in accordance with the current
practice guideline [26], while the dose of curcumin was
derived from a previous report [49]. The optimal dose of
curcumin for HER-2-overexpressed breast cancer is unclear
and needs to be determined for maximum therapeutic eect.
In this study, we showed that curcumin could reduce
the cell viability of both HER-2-overexpressed herceptin-
sensitive BT-474 cells and herceptin-resistant SK-BR-3-hr
breast cancer cells. In the BT-474 xenograft model, though
not as much as herceptin, curcumin did eectively decrease
the tumor size. The combination of curcumin with her-
ceptin was not better than herceptin alone; however, the
combination of taxol and curcumin had an antitumor eect
comparable with taxol and herceptin. The results, both in
vitro and in vivo, suggested that curcumin has the treatment
potential for HER-2-overexpressed breast cancer.
Conflict of Interests
The authors declare that they have no conflict of interests.
Evidence-Based Complementary and Alternative Medicine 11
Acknowledgment
C.-W. Chi and D.-R. Chen equally contributed to the paper.
References
[1]S.Y.Jung,W.Han,J.W.Leeetal.,“Ki-67expressiongives
additional prognostic information on St. Gallen 2007 and
adjuvant! online risk categories in early breast cancer,Annals
of Surgical Oncology, vol. 16, no. 5, pp. 1112–1121, 2009.
[2] V. Ludovini, S. Gori, M. Colozza et al., “Evaluation of serum
HER2 extracellular domain in early breast cancer patients:
correlation with clinicopathological parameters and survival,
Annals of Oncology, vol. 19, no. 5, pp. 883–890, 2008.
[3] D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich,
and W. L. McGuire, “Human breast cancer: correlation of
relapse and survival with amplification of the HER-2/neu
oncogene,Science, vol. 235, no. 4785, pp. 177–182, 1987.
[4] R. M. Hudziak, J. Schlessinger, and A. Ullrich, “Increased
expression of the putative growth factor receptor p185HER2
causes transformation and tumorigenesis of NIH 3T3 cells,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 84, no. 20, pp. 7159–7163, 1987.
[5]M.F.Press,M.C.Pike,V.R.Chazinetal.,“Her-2/neu
expression in node-negative breast cancer: Direct tissue
quantitation by computerized image analysis and association
of overexpression with increased risk of recurrent disease,
Cancer Research, vol. 53, no. 20, pp. 4960–4970, 1993.
[6] R. Seshadri, F. A. Firgaira, D. J. Horsfall, K. McCaul, V. Setlur,
and P. Kitchen, “Clinical significance of HER-2/neu oncogene
amplification in primary breast cancer,Journal of Clinical
Oncology, vol. 11, no. 10, pp. 1936–1942, 1993.
[7] D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemo-
therapy plus a monoclonal antibody against her2 for metastat-
ic breast cancer that overexpresses HER2,The New England
Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001.
[8] M. D. Pegram, A. Lipton, D. F. Hayes et al., “Phase II study
of receptor-enhanced chemosensitivity using recombinant
humanized anti-p185(HER2/neu) monoclonal antibody plus
cisplatin in patients with HER2/neu-overexpressing metastatic
breast cancer refractory to chemotherapy treatment,Journal
of Clinical Oncology, vol. 16, no. 8, pp. 2659–2671, 1998.
[9] M. A. Cobleigh, C. L. Vogel, D. Tripathy et al., “Multina-
tional study of the ecacy and safety of humanized anti-
HER2 monoclonal antibody in women who have HER2-
overexpressing metastatic breast cancer that has progressed
after chemotherapy for metastatic disease,Journal of Clinical
Oncology, vol. 17, no. 9, pp. 2639–2648, 1999.
[10] M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al.,
“Trastuzumab after adjuvant chemotherapy in HER2-positive
breast cancer,The New England Journal of Medicine, vol. 353,
no. 16, pp. 1659–1672, 2005.
[11] E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus
adjuvant chemotherapy for operable HER2-positive breast
cancer,The New England Journal of Medicine, vol. 353, no. 16,
pp. 1673–1684, 2005.
[12] H. Joensuu, P. L. Kellokumpu-Lehtinen, P. Bono et al., “Adju-
vant docetaxel or vinorelbine with or without trastuzumab for
breast cancer,The New England Journal of Medicine, vol. 354,
no. 8, pp. 809–820, 2006.
[13] C. L. Vogel, M. A. Cobleigh, D. Tripathy et al., “Ecacy and
safety of trastuzumab as a single agent in first-line treatment
of HER2-overexpressing metastatic breast cancer,Journal of
Clinical Oncology, vol. 20, no. 3, pp. 719–726, 2002.
[14] P. R. Pohlmann, I. A. Mayer, and R. Mernaugh, “Resistance to
trastuzumab in breast cancer,Clinical Cancer Research, vol.
15, no. 24, pp. 7479–7491, 2009.
[15] F. J. Esteva, V. Valero, D. Booser et al., “Phase II study of
weekly docetaxel and trastuzumab for patients with HER-2-
overexpressing metastatic breast cancer, Journal of Clinical
Oncology, vol. 20, no. 7, pp. 1800–1808, 2002.
[16] B. B. Aggarwal, A. Kumar, and A. C. Bharti, “Anticancer poten-
tial of curcumin: preclinical and clinical studies,Anticancer
Research, vol. 23, no. 1 A, pp. 363–398, 2003.
[17] R. A. Sharma, A. J. Gescher, and W. P. Steward, “Curcumin:
the story so far,European Journal of Cancer, vol. 41, no. 13,
pp. 1955–1968, 2005.
[18] D. P. Chauhan, “Chemotherapeutic potential of curcumin for
colorectal cancer,Current Pharmaceutical Design, vol. 8, no.
19, pp. 1695–1706, 2002.
[19] A. Chen, J. Xu, and A. C. Johnson, “Curcumin inhibits human
colon cancer cell growth by suppressing gene expression
of epidermal growth factor receptor through reducing the
activity of the transcription factor Egr-1,Oncogene, vol. 25,
no. 2, pp. 278–287, 2006.
[20] Z. M. Shao, Z. Z. Shen, C. H. Liu et al., “Curcumin exerts
multiple suppressive eects on human breast carcinoma cells,
International Journal of Cancer, vol. 98, no. 2, pp. 234–240,
2002.
[21] L. Korutla, J. Y. Cheung, J. Mendelsohn, and R. Kumar, “Inhi-
bition of ligand-induced activation of epidermal growth factor
receptor tyrosine phosphorylation by curcumin,Carcinogen-
esis, vol. 16, no. 8, pp. 1741–1745, 1995.
[22] T. Dorai, N. Gehani, and A. Katz, “Therapeutic potential of
curcumin in human prostate cancer. II. Curcumin inhibits
tyrosine kinase activity of epidermal growth factor receptor
and depletes the protein,Molecular Urology,vol.4,no.1,pp.
1–6, 2000.
[23] R. L. Hong, W. H. Spohn, and M. C. Hung, “Curcumin in-
hibits tyrosine kinase activity of p185neu and also depletes
p185neu1,Clinical Cancer Research, vol. 5, no. 7, pp. 1884–
1891, 1999.
[24] A. R. Hussain, M. Al-Rasheed, P. S. Manogaran et al., “Cur-
cumin induces apoptosis via inhibition of PI3’-kinase/AKT
pathway in acute T cell leukemias,Apoptosis,vol.11,no.2,
pp. 245–254, 2006.
[25] L. Camacho-Barquero, I. Villegas, J. M. S´
anchez-Calvo et al.,
“Curcumin, a Curcuma longa constituent, acts on MAPK p38
pathway modulating COX-2 and iNOS expression in chronic
experimental colitis,International Immunopharmacology, vol.
7, no. 3, pp. 333–342, 2007.
[26] R. J. Winn and J. S. McClure, “NCCN Clinical Practice Guid-
lines in Oncology: Breast Cancer,” 2010, http://www.nccn.org/
professionals/physician gls/PDF/breast.pdf.
[27] A. Lin and M. Karin, “NF-κB in cancer: a marked target,
Seminars in Cancer Biology, vol. 13, no. 2, pp. 107–114, 2003.
[28] D.K.Biswas,S.C.Dai,A.Cruz,B.Weiser,E.Graner,andA.
B.Pardee,“ThenuclearfactorkappaB(NF-κB): a potential
therapeutic target for estrogen receptor negative breast can-
cers,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 98, no. 18, pp. 10386–10391,
2001.
[29] C. Nakanishi and M. Toi, “Nuclear factor-κB inhibitors as
sensitizers to anticancer drugs,Nature Re views Cancer, vol.
5, no. 4, pp. 297–309, 2005.
12 Evidence-Based Complementary and Alternative Medicine
[30] D. K. Biswas and J. D. Iglehart, “Linkage between EGFR family
receptors and nuclear factor KappaB (NF-κB) signaling in
breast cancer,Journal of Cellular Physiology, vol. 209, no. 3,
pp. 645–652, 2006.
[31] B. B. Aggarwal, S. Shishodia, Y. Takada et al., “Curcumin sup-
presses the paclitaxel-induced nuclear factor-κBpathwayin
breast cancer cells and inhibits lung metastasis of human
breast cancer in nude mice,Clinical Cancer Research, vol. 11,
no. 20, pp. 7490–7498, 2005.
[32] A. M. Kamat, G. Sethi, and B. B. Aggarwal, “Curcumin poten-
tiates the apoptotic eects of chemotherapeutic agents and
cytokines through down-regulation of nuclear factor-κBand
nuclear factor-κB-regulated gene products in IFN-α-sensitive
and IFN-α-resistant human bladder cancer cells,Molecular
Cancer Therapeutics, vol. 6, no. 3, pp. 1022–1030, 2007.
[33] H. J. Kang, S. H. Lee, J. E. Price, and L. S. Kim, “Curcumin
suppresses the paclitaxel-induced nuclear factor-κB in breast
cancer cells and potentiates the growth inhibitory eect of
paclitaxel in a breast cancer nude mice model,Breast Journal,
vol. 15, no. 3, pp. 223–229, 2009.
[34] N. Normanno, M. Campiglio, F. Perrone, A. De Luca, and S.
Menard, “Is the gefitinib plus trastuzumab combination feasi-
ble in breast cancer patients?” Annals of Oncology, vol. 16, no.
10, p. 1709, 2005.
[35] S. L. Moulder and C. L. Arteaga, “A phase I/II trial of
trastuzumab and gefitinib in patients with metastatic breast
cancer that overexpresses HER2/neu (ErbB-2),Clinical Breast
Cancer, vol. 4, no. 2, pp. 142–145, 2003.
[36] S. L. Moulder, F. M. Yakes, S. K. Muthuswamy, R. Bianco,
J. F. Simpson, and C. L. Arteaga, “Epidermal growth factor
receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa)
inhibits HER2/neu (erbB2)-overexpressing breast cancer cells
in vitro and in vivo,Cancer Research, vol. 61, no. 24, pp. 8887–
8895, 2001.
[37] W.Xia,C.M.Gerard,L.Liu,N.M.Baudson,T.L.Ory,and
N. L. Spector, “Combining lapatinib (GW572016), a small
molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases,
with therapeutic anti-ErbB2 antibodies enhances apoptosis of
ErbB2-overexpressing breast cancer cells,Oncogene, vol. 24,
no. 41, pp. 6213–6221, 2005.
[38] V. Vichai and K. Kirtikara, “Sulforhodamine B colorimetric
assay for cytotoxicity screening,Nature Protocols, vol. 1, no.
3, pp. 1112–1116, 2006.
[39] T. C. Chou and P. Talalay, “A simple generalized equation
for the analysis of multiple inhibitions of Michaelis-Menten
kinetic systems,Journal of Biological Chemistry, vol. 252, no.
18, pp. 6438–6442, 1977.
[40] T. C. Chou and P. Talalay, “Applications of the median eect
principle for the assessment of low dose risk of carcinogenesis
and for the quantitation of synergism and antagonism of
chemotherapeutic agents in new avenues in development
cancer chemotherapy,” in Bristol-Myers Symposium,K.R.
Harra and C. TA, Eds., pp. 37–64, Academic Press, New York,
NY, USA, 1987.
[41] D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,
Cell, vol. 100, no. 1, pp. 57–70, 2000.
[42] K. E. Longva, N. M. Pedersen, C. Haslek˚
as,E.Stang,andI.H.
Madshus, “Herceptin-induced inhibition of ErbB2 signaling
involves reduced phosphorylation of Akt but not endocytic
down-regulation of ErbB2,International Journal of Cancer,
vol. 116, no. 3, pp. 359–367, 2005.
[43] S. Singh, Q. Shi, S. T. Bailey et al., “Nuclear factor-
κB activation: a molecular therapeutic target for estrogen
receptor-negative and epidermal growth factor receptor family
receptor-positive human breast cancer,Molecular Cancer
Therapeutics, vol. 6, no. 7, pp. 1973–1982, 2007.
[44] N. R. Monks, D. K. Biswas, and A. B. Pardee, “Blocking anti-
apoptosis as a strategy for cancer chemotherapy: NF-κBasa
target,Journal of Cellular Biochemistry, vol. 92, no. 4, pp. 646–
650, 2004.
[45] A. L. Chen, C. H. Hsu, J. K. Lin et al., “Phase I clinical trial of
curcumin, a chemopreventive agent, in patients with high-risk
or pre-malignant lesions,Anticancer Research, vol. 21, no. 4 B,
pp. 2895–2900, 2001.
[46] M. L ´
opez-L`
azaro, “Anticancer and carcinogenic properties of
curcumin: considerations for its clinical development as a can-
cer chemopreventive and chemotherapeutic agent,Molecular
Nutrition and Food Research, vol. 52, no. 1, pp. S103–S127,
2008.
[47] C. V. Rao, A. Rivenson, B. Simi, and B. S. Reddy, “Chemo-
prevention of colon carcinogenesis by dietary curcumin,
a naturally occurring plant phenolic compound,Cancer
Research, vol. 55, no. 2, pp. 259–266, 1995.
[48] K. B. Soni and R. Kuttan, “Eect of oral curcumin adminis-
tration on serum peroxides and cholesterol levels in human
volunteers,Indian Journal of Physiology and Pharmacology,
vol. 36, no. 4, pp. 273–275, 1992.
[49] C. C. Su, J. S. Yang, C. C. Lu et al., “Curcumin inhibits human
lung large cell carcinoma cancer tumour growth in a murine
xenograft model,” Phytotherapy Research, vol. 24, no. 2, pp.
189–192, 2010.
... In between 15 and 25% of BC patients, the oncoprotein HER2 is overexpressed. In both SK-BR-3-h and BT-474 cells, CUR reduced the expression of NF-κB, Akt, and MAPK as well as the HER2 oncoprotein [95]. Additionally, CUR adapted p65-NF-κB-p300 crosstalk in favor of p53-p300 for BC, increasing the effectiveness of chemotherapy [96]. ...
Article
Full-text available
Breast cancer (BC) bone metastasis poses a significant clinical challenge due to its impact on patient prognosis and quality of life. Curcumin (CUR), a natural polyphenol compound found in turmeric, has shown potential in cancer therapy due to its anti-inflammatory, antioxidant, and anticancer properties. However, its metabolic instability and hydrophobicity have hindered its clinical applications, leading to a short plasma half-life, poor absorption, and low bioavailability. To enhance the drug-like properties of CUR, nanotechnology-based delivery strategies have been employed, utilizing polymeric, lipidic, and inorganic nanoparticles (NPs). These approaches have effectively overcome CUR’s inherent limitations by enhancing its stability and cellular bioavailability both in vitro and in vivo. Moreover, targeting molecules with high selectivity towards bone metastasized breast cancer cells can be used for site specific delivery of curcumin. Alendronate (ALN), a bone-seeking bisphosphonate, is one such moiety with high selectivity towards bone and thus can be effectively used for targeted delivery of curcumin loaded nanocarriers. This review will detail the process of bone metastasis in BC, elucidate the mechanism of action of CUR, and assess the efficacy of nanotechnology-based strategies for CUR delivery. Specifically, it will focus on how these strategies enhance CUR’s stability and improve targeted delivery approaches in the treatment of BC bone metastasis.
... [58] Curcumin (1) (1) therapy. [59] Curcumin (1) exhibited dose-and time-dependent growth inhibitory effects on BT-20, T47D, SK-BR3, and MCF-7 BC cell lines, and was also correlated with ornithine decarboxylase suppression. [60] In ER-positive MCF-7 cells, curcumin (1) suppressed the expression of ER downstream genes, such as pS2 and TGF-β, and also exerted potent anti-invasive effects in vitro on ER-negative MDA-MB-231 BC cells whereby curcumin (1) may prevent MDA-MB-231 cells from invasion and metastasis by targeting Gli1 in the Hedgehog/Gli1 signaling pathway. ...
... The effect of curcumin on HER-2 overexpressed breast cancer cell lines, specifically, BT-474 human ductal breast cancer cells and SKBR3, was evaluated by Lai et al. According to their results, the downregulation of HER-2 and EGFR in curcumin-treated cells was strongly related to the inhibition of signaling pathways, including PI3K/Akt (in which a decrease in the phosphorylation status of Akt was observed after curcumin treatment), MAPK, and NF-κB [64]. ...
Article
Full-text available
Simple Summary Cancer has a major impact on societies across the world. In an attempt to find new treatment options for cancer, attention has shifted to natural compounds. Curcumin is a polyphenol isolated from the roots of turmeric that possesses many biological properties. It acts on the regulation of different aspects of tumor development and interconnects with major signaling pathways that are dysregulated in cancer, such as the phosphatidylinositol-3-kinase/protein kinase B pathway. In this review, the diverse effects of curcumin on the regulation of this pathway in different malignancies will be discussed. Abstract Cancer is a life-threatening disease and one of the leading causes of death worldwide. Despite significant advancements in therapeutic options, most available anti-cancer agents have limited efficacy. In this context, natural compounds with diverse chemical structures have been investigated for their multimodal anti-cancer properties. Curcumin is a polyphenol isolated from the rhizomes of Curcuma longa and has been widely studied for its anti-inflammatory, anti-oxidant, and anti-cancer effects. Curcumin acts on the regulation of different aspects of cancer development, including initiation, metastasis, angiogenesis, and progression. The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) pathway is a key target in cancer therapy, since it is implicated in initiation, proliferation, and cancer cell survival. Curcumin has been found to inhibit the PI3K/Akt pathway in tumor cells, primarily via the regulation of different key mediators, including growth factors, protein kinases, and cytokines. This review presents the therapeutic potential of curcumin in different malignancies, such as glioblastoma, prostate and breast cancer, and head and neck cancers, through the targeting of the PI3K/Akt signaling pathway.
... Administrated 20 to 80 μM of curcumin leads to estrogen receptor α and p53 protein expression markedly reduced [48]. Estrogen receptor-positive cell lines such as MCF7 and BT474 have a higher half-maximal inhibitory concentration (IC50) for curcumin than estrogen receptor-negative cell lines (e.g., MBA-MB-231 and SKBR3) [49,50]. It shows that curcumin may ex-ert some of its protective effects by other mechanisms and pathways. ...
Article
Full-text available
Curcumin, a polyphenolic derivative of Curcuma longa rhizome, has numerous beneficial effects, including antibacterial, anti-inflammatory, antiviral, antioxidant, antifungal, anti-ischemic, anti-cancer, hypoglycemic, nephroprotective, antirheumatic, hepato-protective, and antimutagenic. Curcumin has indicated the capability to exert anti-cancer activity by multifunctional mechanisms, such as induction of apoptosis, inhibition of cancer cell proliferation, cell cycle regulation, chemotherapeutic intestinal absorption, and modification of several cancer cell types signaling pathways. Several studies have shown that curcumin may have protective effects against tumors of the reproductive system. Reproductive system cancers may cause many undesirable physical and, especially, mental disorders. Infertility and its mental consequences, sexual problems, chemotherapy and surgery-related adverse effects, substantial economic burden, and death are the most common complications regarding the cancers of the reproductive system. By modulating several reproductive cancer hallmarks such as signaling pathways, multiple drug resistance, cancer cell growth and proliferation, tumor angiogenesis, and transcription factors, curcumin could be used as a safe, non-toxic, cheap, and easily accessible drug for treating different types of reproductive cancers. [GMJ.2021;10:e2178]
... Curcumin interferes with the PI3K/Akt/mTOR pathway through its regulatory role on key molecule players of AKT, PTEN, HER2, and mTOR which may facilitate the inhibition of cellular growth, invasion, and metastasis in breast cancer [95,96] . This molecule is a potential breast cancer treatment agent due to its activity on a different pathway. ...
Article
Full-text available
One of the primary concerns for women in good health is breast cancer. The most typical hazardous growth is this one. It spreads easily, and the clinical conditions are terrible. Bosom illness is the second‐most common type of malignant tumor that regularly causes women to pass away in the U.S. bosom malignant growth is the most well‐known disease among women worldwide, with 2.1 million cases reported in 2018 and more than 620,000 fatalities per year. Natural components are viewed as promising alternatives for the development of novel anti‐tumor drugs. Curcumin, also termed diferuloylmethane, is a yellow pigment made by the turmeric plant, Curcuma longa Linn. It is the curcuminoid and polyphenol present in the plant’s root that is most abundant. The antioxidant and anti‐inflammatory qualities of curcumin have been demonstrated, and it is frequently utilized in traditional medicine and cuisine. Due to its sophisticated pharmacological capabilities of chemoprevention and anticancer effects, curcumin, the main component of turmeric, has been linked to the treatment of breast cancer. The morbidity or mortality of the disease have not been significantly decreased by current breast cancer treatment options such as surgery, radiation, adjuvant chemotherapy, or hormone therapy. The expansion, estrogen receptor (trauma center), and human epidermal development factor receptor 2 (HER2) pathways are all involved in the activity of curcumin in illness. In breast cancer cells, curcumin is also known to regulate microRNA, cell stage-related characteristics, and apoptosis. This study reviews recent research on the atomic targets and anticancer effects of curcumin in breast cancer.
Article
Full-text available
Breast cancer is a common form of cancer among women characterized by the growth of malignant cells in the breast tissue. The most common treatments for this condition include chemotherapy, surgical intervention, radiation therapy, hormone therapy, and biological therapy. The primary issues associated with chemotherapy and radiation therapy are their adverse events and significant financial burden among patients in underdeveloped countries. This highlights the need to explore and develop superior therapeutic options that are less detrimental and more economically efficient. Plants provide an abundant supply of innovative compounds and present a promising new avenue for investigating cancer. Plants and their derivations are undergoing a revolution due to their reduced toxicity, expediency, cost‐effectiveness, safety, and simplicity in comparison to conventional treatment methods. Natural products are considered promising candidates for the development of anticancer drugs, due perhaps to the diverse pleiotropic effects on target events. The effects of plant‐derived products are limited to cancer cells while leaving healthy cells unaffected. Identification of compounds with strong anticancer properties and development of plant‐based medications for cancer treatment might be crucial steps in breast cancer therapy. Although bioactive compounds have potent anticancer properties, they also have drawbacks that need to be resolved before their application in clinical trials and improved for the approved drugs. This study aims to give comprehensive information on known anticancer compounds, including their sources and molecular mechanisms of actions, along with opportunities and challenges in plant‐based anticancer therapies.
Chapter
Cancer, a potent and destructive ailment, has been a longstanding health concern for communities and a persistent challenge in the healthcare system for decades. Thus, it demands innovative approaches for effective diagnosis and treatment. In conjunction with that, this chapter explores the paradigm shift in cancer therapy through the integration of metabolomics and plant-based pharmaceuticals. It highlights the synergy between these approaches, elucidating the discovery of novel natural products, known as biomarkers, for combating cancer. The integration not only facilitates biomarker discovery but also unknots the intricate mechanisms underlying anticancer effects of plant-derived compounds, revolutionizing cancer treatment with personalized and effective therapeutic strategies. The comprehensive exploration in this chapter also encompasses the significance of metabolomics in cancer research, the potential of plant-based pharmaceuticals, and the integration of metabolomics with various omics data for a multidimensional view of cancer metabolism. It investigates metabolomics techniques, data acquisition, and analysis methods while emphasizing the integrated approach for biomarker identification. The integration of metabolomics with genomics, transcriptomics, and proteomics data is discussed, showcasing case studies of successful integrated approaches. Additionally, the chapter explores plant-based cancer biomarkers and concludes by emphasizing the validation of identified biomarkers, addressing challenges, and contemplating future directions for personalized medicine and targeted therapies in the fight against cancer. This comprehensive exploration serves as a valuable resource for researchers and clinicians harnessing metabolomics and plant-based pharmaceuticals in the battle against cancer.
Article
Full-text available
We compared docetaxel with vinorelbine for the adjuvant treatment of early breast cancer. Women with tumors that overexpressed HER2/neu were also assigned to receive concomitant treatment with trastuzumab or no such treatment. We randomly assigned 1010 women with axillary-node-positive or high-risk node-negative cancer to receive three cycles of docetaxel or vinorelbine, followed by (in both groups) three cycles of fluorouracil, epirubicin, and cyclophosphamide. The 232 women whose tumors had an amplified HER2/neu gene were further assigned to receive or not to receive nine weekly trastuzumab infusions. The primary end point was recurrence-free survival. Recurrence-free survival at three years was better with docetaxel than with vinorelbine (91 percent vs. 86 percent; hazard ratio for recurrence or death, 0.58; 95 percent confidence interval, 0.40 to 0.85; P=0.005), but overall survival did not differ between the groups (P=0.15). Within the subgroup of patients who had HER2/neu-positive cancer, those who received trastuzumab had better three-year recurrence-free survival than those who did not receive the antibody (89 percent vs. 78 percent; hazard ratio for recurrence or death, 0.42; 95 percent confidence interval, 0.21 to 0.83; P=0.01). Docetaxel was associated with more adverse effects than was vinorelbine. Trastuzumab was not associated with decreased left ventricular ejection fraction or cardiac failure. Adjuvant treatment with docetaxel, as compared with vinorelbine, improves recurrence-free survival in women with early breast cancer. A short course of trastuzumab administered concomitantly with docetaxel or vinorelbine is effective in women with breast cancer who have an amplified HER2/neu gene. (International Standard Randomised Controlled Trial number, ISRCTN76560285.).
Article
Full-text available
HER2 is a transmembrane oncoprotein encoded by the HER2/neu gene and is overexpressed in approximately 20 to 25% of invasive breast cancers. It can be therapeutically targeted by trastuzumab, a humanized IgG1 kappa light chain monoclonal antibody. Although trastuzumab is currently considered one of the most effective treatments in oncology, a significant number of patients with HER2-overexpressing breast cancer do not benefit from it. Understanding the mechanisms of action and resistance to trastuzumab is therefore crucial for the development of new therapeutic strategies. This review discusses proposed trastuzumab mode of action as well as proposed mechanisms for resistance. Mechanisms for resistance are grouped into four main categories: (1) obstacles preventing trastuzumab binding to HER2; (2) upregulation of HER2 downstream signaling pathways; (3) signaling through alternate pathways; and (4) failure to trigger an immune-mediated mechanism to destroy tumor cells. These potential mechanisms through which trastuzumab resistance may arise have been used as a guide to develop drugs, presently in clinical trials, to overcome resistance. The mechanisms conferring trastuzumab resistance, when completely understood, will provide insight on how best to treat HER2-overexpressing breast cancer. The understanding of each mechanism of resistance is therefore critical for the educated development of strategies to overcome it, as well as for the development of tools that would allow definitive and efficient patient selection for each therapy. (Clin Cancer Res 2009;15(24):7479-91).
Article
Full-text available
We sought to determine the significance of Ki-67, one of the tumor cell proliferation markers, as a useful prognostic factor in early breast cancer. A total of 1080 consecutive patients with stage I or II breast cancer that underwent surgery between 1998 and 2003 were enrolled. Patients were categorized on the basis of the 2007 St. Gallen consensus and Adjuvant! Online. The expression of Ki-67 in the tumor was assayed by immunohistochemistry (cutoff value, 10%). Univariate analysis determined that tumor size, lymph node involvement, histologic grade, estrogen receptor, progesterone receptor, bcl-2, and Ki-67 (> or =10%) were statistically significant for both overall survival (OS) and distant metastasis-free survival (DFS). Of these factors, lymph node involvement and high Ki-67 expression were identified as independent prognostic factors for OS and DFS on the basis of multivariate analysis. The survivals of intermediate- and high-risk groups according to 2007 St. Gallen consensus were further separated by Ki-67 expression level (5-year DFS rate = 91.9% vs. 86.3% for Ki-67 < 10% and > or = 10%, respectively in intermediate-risk group (P = .01); 5-year DFS rate = 82.5% vs. 61.4% for Ki-67 < 10% and > or = 10%, respectively in high-risk group (P = .01)). The survivals of low- and high-risk groups according to Adjuvant! Online were further separated by Ki-67 expression level (5-year DFS rate = 97.8% vs. 89.5% for Ki-67 < 10% and > or = 10%, respectively in low-risk group (P = .02); 5-year DFS rate = 9.4% vs. 82.6% for Ki-67 < 10% and > or = 10% in high-risk group (P = .005)). Ki-67 is an independent prognostic factor for DFS and OS in early breast cancer and can provide additional prognostic information on the risk stratification with the use of the 2007 St. Gallen consensus and Adjuvant! Online.
Article
Full-text available
The summation of the effects of two or more reversible inhibitors of various types on the initial velocity of enzyme systems obeying Michaelis-Menten kinetics is described by the the general relation: (formula: see text) wherein v1,2,3...n is the velocity of reaction in the simultaneous presence of n inhibitors, vi is the velocity observed in the presence of each individual inhibitor, and v0 is the velocity in the absence of inhibition. The derivation is based on the assumption that each enzyme species can combine with no more than one of the inhibitors (i.e. the inhibitors are mutually exclusive). The above relationship holds irrespective of the number of inhibitors, the type of inhibition (competitive, noncompetitive, or uncompetitive), or the kinetic mechanism (sequential or ping-pong) of the enzyme reaction under consideration. Deviations from this equality define synergism or antagonism of inhibitors depending on whether the value of the left side of the above equation is greater or smaller than the right, respectively. Knowledge of the kinetic constants for substrates and inhibitors is not required. If two or more inhibitors act independently (i.e. are not mutually exclusive), their combined effects are necessarily synergistic. Under certain circumstances, described in the text, mutually nonexclusive inhibitors obey the fractional velocity product relationship: v1,2,3...n/v0 = (v1/v0) x (v2/v0) x (v3/v0)...(vn/v0).
Article
The HER-2/neu oncogene is a member of the crbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of die HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or padiogenesis of human breast cancer.
Article
The imbalance between proliferation and programmed cell death (apoptosis) is one of the critical cellular events that lead to oncogenesis. While there is no doubt that uncontrolled cell proliferation is essential for the development of cancer, deregulation of apoptosis may play an equally important role in this process. Inhibition of apoptosis prevents the death of tumor cells with DNA damage either associated with carcinogenic initiation or cancer therapy. The transcription factor NF-κB is a key regulator in oncogenesis. By promoting proliferation and inhibiting apoptosis, NF-κB tips the balance between proliferation and apoptosis toward malignant growth in tumor cells.
Article
Curcumin can decrease viable cells through the induction of apoptosis in human lung cancer NCI-H460 cells in vitro. However, there are no reports that curcumin can inhibit cancer cells in vivo. In this study, NCI-H460 lung tumour cells were implanted directly into nude mice and divided randomly into four groups to be treated with vehicle, curcumin (30 mg/kg of body weight), curcumin (45 mg/kg of body weight) and doxorubicin (8 mg/kg of body weight). Each agent was injected once every 4 days intraperitoneally (i.p.), with treatment starting 4 weeks after inoculation with the NCI-H460 cells. Treatment with 30 mg/kg and 45 mg/kg of curcumin or with 8 mg/kg of doxorubicin resulted in a reduction in tumour incidence, size and weight compared with the control group. The findings indicate that curcumin can inhibit tumour growth in a NCI-H460 xenograft animal model in vivo.
Article
Most anticancer agents activate nuclear factor kappa B (NF-kappaB), which can mediate cell survival, proliferation, and metastasis. Curcumin has been shown to inhibit the growth of various cancer cells, without toxicity to normal cells. The antitumor effects of curcumin could be due in part to the inactivation of NF-kappaB. We hypothesize that blocking NF-kappaB activity may augment paclitaxel cancer chemotherapy. In this study, we investigated whether the inactivation of NF-kappaB by curcumin would enhance the efficacy of paclitaxel for inhibiting breast cancer growth in vitro and in vivo. We confirmed that curcumin inhibited paclitaxel-induced activation of NF-kappaB and potentiated the growth inhibitory effect of paclitaxel in MDA-MB-231 breast cancer cells. The combination of curcumin with paclitaxel elicited significantly greater inhibition of cell growth and more apoptosis, compared with either agent alone. In an experimental breast cancer murine model using MDA-MB-231 cells, combination therapy with paclitaxel and curcumin significantly reduced tumor size and decreased tumor cell proliferation, increased apoptosis, and decreased the expression of matrix metalloprotease 9 compared with either agent alone. These results clearly suggest that a curcumin-paclitaxel combination could be a novel strategy for the treatment of breast cancer.
Article
The effect of curcumin administration in reducing the serum levels of cholesterol and lipid peroxides was studied in ten healthy human volunteers, receiving 500 mg of curcumin per day for 7 days. A significant decrease in the level of serum lipid peroxides (33%), increase in HDL Cholesterol (29%), and a decrease in total serum cholesterol (11.63%) were noted. As curcumin reduced serum lipid peroxides and serum cholesterol, the study of curcumin as a chemopreventive substance against arterial diseases is suggested.